Recent Company News

• 07:10 AM ET Mar 26, 2026
  

  Agomab receives U.S. Patent for AGMB-447 ($12.86, 0.00)

• 12:45 PM ET Mar 08, 2026
  

  StreetAccount Sector Summary: Healthcare Monthly Recap - February 2026

• 04:54 PM ET Mar 03, 2026
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 08:42 AM ET Mar 03, 2026
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 06:22 AM ET Mar 03, 2026
  

  AgomAb Therapeutics NV initiated outperform at Leerink Partners ($16.21, 0.00)

• 06:04 AM ET Mar 03, 2026
  

  AgomAb Therapeutics NV initiated overweight at Morgan Stanley ($16.21, 0.00)

• 06:03 AM ET Mar 03, 2026
  

  AgomAb Therapeutics NV initiated overweight at JPMorgan ($16.21, 0.00)

• 02:00 PM ET Feb 09, 2026
  

  StreetAccount Summary - Private Company Weekly Recap - Week of 2-Feb

• 12:40 PM ET Feb 06, 2026
  

  AgomAb Therapeutics NV IPO opens at $14.70 on the Nasdaq

• 10:49 AM ET Feb 06, 2026
  

  AgomAb Therapeutics NV now indicated to open at $15.25/ADS, priced at $16